On Monday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened lower -5.66% from the last session, before settling in for the closing price of $2.12. Price fluctuations for CTMX have ranged from $0.40 to $3.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -86.47% at the time writing. With a float of $120.75 million, this company’s outstanding shares have now reached $164.91 million.
Let’s look at the performance matrix of the company that is accounted for 121 employees.
CytomX Therapeutics Inc (CTMX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 26.78%, while institutional ownership is 65.38%. The most recent insider transaction that took place on Jun 16 ’25, was worth 28,540. In this transaction Chief Financial Officer of this company sold 10,614 shares at a rate of $2.69, taking the stock ownership to the 226,271 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Chief Financial Officer sold 1,641 for $2.95, making the entire transaction worth $4,841. This insider now owns 199,385 shares in total.
CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 0.07 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.13) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -86.47% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.57, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 3.44 million, a positive change from its year-to-date volume of 3.31 million. As of the previous 9 days, the stock’s Stochastic %D was 57.74%.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 59.37%, which indicates a significant increase from 39.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.27, while its 200-day Moving Average is $1.38. Nevertheless, the first resistance level for the watch stands at $2.10 in the near term. At $2.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.26. If the price goes on to break the first support level at $1.94, it is likely to go to the next support level at $1.87. Assuming the price breaks the second support level, the third support level stands at $1.78.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are currently 164,913K shares outstanding in the company with a market cap of 329.82 million. Presently, the company’s annual sales total 138,100 K according to its annual income of 31,870 K. Last quarter, the company’s sales amounted to 18,660 K and its income totaled -150 K.
